Herceptin for glioblastoma – pro
Trastutumab as a treatment for glioblastoma is in the intitial stages of being studied. I was not able to find studies of clinical treatment, especially via the intrevaentricular route of administration but there are centers where this is being done singly or in cmbination. The field is currently centered on showing that there is in-vitro effect of this drug on glioblastoma cell lines. Several such pre-clincal studies have been published since 2004 and continue to very recently be published. Clinicaltrials.gov does not list clinical studies of trastuzumab for glioblastoma. This leads me to the conclusion that the filed has not yet even matured to the point of starting human studies. Looking at the issue from this standpint leads to the conclusion that the treatment is highly experimental and should not be approved udner the enclosed evidence based policy.
Ian M Zitron et al, Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies, BMC Cancer 2013, 13:83
Mineo JF, Bordron A, Quintin-Roué I, Loisel S, Ster KL, Buhé V, Lagarde N, Berthou C.
Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas. Br J Cancer. 2004 Sep 13;91(6):1195-9.
J, Siderov, Care with intrathecal trastuzumab The Lancet Oncology, Volume 7, Issue 11, Page 888, November 2006